Search details
1.
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Gynecol Oncol
; 174: 157-166, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37207500
2.
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
Breast Cancer Res Treat
; 179(3): 543-555, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31705351
3.
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Biochem Soc Trans
; 42(4): 822-30, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-25109964
4.
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
J Pathol
; 230(4): 430-40, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23616343
5.
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.
Sci Rep
; 13(1): 7681, 2023 05 11.
Article
in English
| MEDLINE | ID: mdl-37169775
6.
Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.
Cancer Res
; 78(6): 1484-1496, 2018 03 15.
Article
in English
| MEDLINE | ID: mdl-29330144
7.
Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.
Dis Model Mech
; 9(2): 131-40, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26721874
8.
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.
Oncotarget
; 7(10): 11539-52, 2016 Mar 08.
Article
in English
| MEDLINE | ID: mdl-26883193
9.
Src kinase inhibitors: promising cancer therapeutics?
Crit Rev Oncog
; 17(2): 145-59, 2012.
Article
in English
| MEDLINE | ID: mdl-22471705
Results
1 -
9
de 9
1
Next >
>>